Basket trial design in pancreatic and gastrointestinal cancers

The development of new therapies in gastrointestinal oncology remains particularly challenging. Tumours such as pancreatic adenocarcinoma, cholangiocarcinoma, gastric cancer and oesophageal cancer are often diagnosed at advanced stages, display considerable biological heterogeneity and frequently offer limited treatment options after progression on standard therapies.
At the same time, oncology has entered the era of precision medicine. Rather than defining diseases solely by their anatomical origin, researchers increasingly focus on the molecular alterations driving tumour growth. Advances in genomic profiling have revealed that the same actionable biomarker can be detected across multiple tumour types, opening new possibilities for targeted therapeutic development.
Date: November 19, 2026
When patient populations are fragmented by rare molecular alterations, conventional studies can become slow, costly and difficult to recruit. This has led to the emergence of innovative clinical trial designs, including basket trials, umbrella trials and platform trials.
Among these approaches, basket trial design has become a particularly valuable methodology for evaluating therapies targeting specific molecular alterations across multiple cancers. In gastrointestinal oncology, where unmet medical needs remain substantial, basket trials offer an opportunity to accelerate clinical development while generating meaningful evidence in biomarker-selected populations.
This article explores the role of basket trial oncology methodologies in pancreatic and gastrointestinal cancers, explains the principles behind Simon two-stage design, and examines the operational and scientific lessons that sponsors and clinical development teams can draw from a real-world phase II basket trial involving MAPK pathway mutations.
Why pancreatic cancer remains one of the greatest challenges in oncology?
Pancreatic cancer continues to represent one of the most significant unmet medical needs in modern oncology. Globally, more than 530,000 new pancreatic cancer cases are diagnosed each year, making it the eleventh or twelfth most common cancer worldwide depending on reporting methodology. Despite not being among the most frequently diagnosed malignancies, it ranks among the leading causes of cancer-related death globally.
Its prognosis remains particularly poor. According to the National Cancer Institute, the overall five-year survival rate for pancreatic cancer is approximately 13%, one of the lowest among major cancers. Mortality remains remarkably close to incidence, highlighting the aggressive nature of the disease and the limited effectiveness of existing treatment options.
Factors contributing to this reality
First, early detection remains difficult. Symptoms are often non-specific or absent until the disease has progressed. As a result, many patients are diagnosed only after the tumour has become locally advanced or metastatic.
Second, pancreatic tumours exhibit complex biology and frequently develop resistance mechanisms that limit the durability of therapeutic responses. Although advances in chemotherapy regimens, targeted therapies and supportive care have improved outcomes for some patients, long-term survival remains uncommon.
Third, pancreatic cancer lacks a broadly applicable screening strategy, further limiting opportunities for early intervention.
These challenges have intensified efforts to identify new therapeutic targets and more efficient ways of evaluating investigational treatments. Traditional clinical development pathways often struggle to keep pace with increasingly specialised patient populations. When only a subset of patients harbour a targetable biomarker, innovative trial designs become essential.
This is where precision oncology and basket trial design begin to play a pivotal role. By focusing on molecular alterations rather than tumour location alone, researchers can evaluate targeted therapies more efficiently and potentially accelerate access to promising treatments for patients facing diseases with historically poor outcomes.
The rise of precision oncology and biomarker-driven development
For decades, oncology clinical development was largely organised around tumour histology. Patients were grouped according to the organ in which the cancer originated, and treatment strategies were developed within those disease categories.
The emergence of next-generation sequencing and molecular profiling has fundamentally changed this paradigm.
Today, many cancers are understood not only by where they originate but also by the biological pathways driving tumour progression. Genomic testing can identify actionable alterations that may predict sensitivity to specific therapies. These include mutations involving KRAS, NRAS, BRAF, MEK and ERK, many of which participate in the mitogen-activated protein kinase (MAPK) pathway.
The MAPK pathway plays a central role in cell growth, survival and proliferation. Abnormal activation of this pathway can promote oncogenesis across numerous tumour types. Importantly, these alterations are not confined to a single cancer. Similar MAPK pathway mutations can be observed in pancreatic, colorectal, gastric, oesophageal and biliary tract cancers.
This cross-tumour distribution is one of the key drivers behind biomarker-driven trials. Instead of evaluating a targeted agent separately in each cancer type, researchers can investigate whether patients sharing a common molecular alteration may benefit regardless of tumour origin.
For gastrointestinal cancers, this approach is particularly relevant. Many actionable biomarkers occur at relatively low frequencies within individual tumour types. Attempting to conduct separate studies for each subgroup may be operationally inefficient and statistically challenging.
Basket trials provide a practical solution by enabling simultaneous evaluation of biomarker-selected populations across several tumour types. This methodology aligns closely with the objectives of precision oncology: matching the right patient to the right treatment based on tumour biology rather than anatomical classification alone.
What is a basket trial and when should it be used?
Definition and key principles
A basket trial is a clinical trial design that evaluates a therapy in multiple cancer types sharing a common molecular characteristic.
Instead of grouping patients according to tumour location, participants are assigned based on the presence of a predefined biomarker, genetic mutation or biological pathway alteration.
Each tumour type is typically organised into an independent cohort, commonly referred to as a basket. Patients within each basket share both the target biomarker and the same primary cancer type. Outcomes can therefore be analysed separately while still allowing efficient evaluation of a broader molecular hypothesis.
Basket trials are particularly valuable when:
- A biomarker occurs across multiple tumour types.
- Individual patient populations are relatively small.
- Preliminary efficacy signals are needed before larger development programmes.
- Precision medicine strategies are being explored.
- Rare molecular subgroups are difficult to study through traditional trial designs.
Because of these characteristics, basket trial design has become increasingly important in oncology, especially in rare cancers and biomarker-defined populations.
Differences between basket, umbrella and platform trials
Although often grouped together as innovative trial methodologies, basket, umbrella and platform trials serve different purposes.
Basket trials evaluate a single therapy or therapeutic strategy across multiple tumour types sharing a common biomarker.
Umbrella trials focus on a single cancer type but assign patients to different therapies according to their individual molecular profile.
Platform trials use a flexible structure that can add or remove treatments over time while operating within a common master protocol.
| Trial design | Population structure | Main objective |
| Basket trial | Multiple tumour types, one biomarker | Evaluate therapy across cancers |
| Umbrella trial | One tumour type, multiple biomarkers | Match patients to targeted therapies |
| Platform trial | Multiple therapies under one protocol | Continuous treatment evaluation |
Each approach offers advantages.
Basket trials are highly efficient for studying rare biomarkers. Umbrella trials optimise treatment selection within a single disease. Platform trials maximise long-term development flexibility and resource utilisation.
However, basket trials can be challenging when biological behaviour differs substantially between tumour types despite shared molecular alterations. Understanding these differences remains critical when interpreting efficacy signals.
A real-world example: lessons from a phase II basket trial in gastrointestinal cancers
One illustration of how basket trial design supports precision oncology comes from a phase II study conducted with the operational support of Aixial Group, involving patients with advanced gastrointestinal malignancies harbouring MAPK pathway mutations. Through its expertise in oncology clinical development and trial operations, Aixial contributed to the execution of this complex multicentre programme, providing valuable insights into the practical realities of biomarker-driven studies.
The trial was designed around five independent disease-specific baskets:
- Cholangiocarcinoma
- Pancreatic adenocarcinoma
- Colorectal adenocarcinoma
- Oesophageal cancers
- Gastric adenocarcinoma
Rather than conducting separate studies for each indication, investigators adopted a common basket trial framework centred on MAPK pathway alterations. This approach enabled the simultaneous evaluation of a targeted therapeutic strategy across multiple gastrointestinal cancers while preserving independent assessment within each cohort.
From an operational perspective, the study planned to recruit approximately 215 patients across up to 25 sites, illustrating the scale that modern biomarker-driven programmes can reach despite targeting relatively rare molecular populations.
Integrating statistical efficiency through a Simon two-stage design
A defining feature of this study was the implementation of a Simon two-stage design within each basket. Originally developed by Richard Simon for phase II oncology research, this methodology aims to identify promising therapeutic signals while limiting patient exposure to ineffective treatments and reducing unnecessary development costs.
Each basket initially enrolled 13 patients during Stage 1. Once enrolment was completed, recruitment was temporarily paused to allow an interim efficacy review. If at least four patients within a basket achieved a response, that cohort became eligible to proceed to Stage 2 following sponsor and safety monitoring review. Additional patients could then be recruited into that specific basket.
This design illustrates how basket trials combine precision medicine principles with efficient decision-making. Rather than investing equally in all tumour cohorts from the outset, resources can be concentrated on indications demonstrating early evidence of activity. This is particularly valuable in gastrointestinal oncology, where eligible patients often represent highly selected biomarker-defined populations.
Operational realities of running a complex basket trial
While basket trial oncology designs offer clear scientific advantages, their execution remains highly demanding. The study supported by Aixial highlights several operational challenges commonly encountered in precision oncology programmes.
Patient recruitment represented a major consideration. Identifying eligible participants required not only confirmation of tumour histology but also molecular profiling capable of detecting the relevant MAPK pathway alterations. As is often the case in biomarker-driven development, screening activities were significantly more complex than those of traditional oncology studies.
The multi-cohort nature of the programme introduced additional layers of coordination. Recruitment rates varied between baskets, interim analyses occurred independently, and operational teams needed to maintain consistent oversight across numerous stakeholders and sites.
The programme also required sophisticated management of biological samples, laboratory workflows and investigational product logistics. To mitigate potential risks, dedicated processes were implemented to support compliant specimen collection, timely shipment and coordination with multiple laboratories. Aixial also helped address drug supply risks by securing product availability in advance when demand threatened continuity of supply.
Like many studies initiated during the COVID-19 period, the trial faced site start-up challenges linked to staffing shortages and increased administrative burden. Close collaboration between sponsors, sites and study teams, including tailored site support and flexible start-up processes, helped maintain study momentum despite these constraints.
Key lessons for clinical development teams
Beyond its scientific objectives, this programme provides a useful example of the operational maturity required to successfully deliver innovative clinical trial designs.
The experience demonstrates that the success of a basket trial does not depend solely on its statistical framework. Equally important are robust site engagement strategies, effective biomarker screening pathways, strong specimen management processes and close coordination between sponsors, CROs, laboratories and investigators.
As precision oncology continues to evolve, these operational considerations will increasingly determine the ability of drug developers to translate promising biological hypotheses into executable clinical programmes. The lessons learned from this type of study highlight why both methodological innovation and operational excellence are essential components of modern oncology clinical development.
Benefits and limitations of basket trials
Key advantages
Basket trials have become increasingly popular because they address several limitations of conventional oncology studies.
The primary advantage is efficiency. Multiple tumour indications can be evaluated simultaneously under a shared framework.
Additional benefits include:
- Faster identification of efficacy signals.
- Reduced duplication of development activities.
- Better utilisation of clinical trial resources.
- Improved feasibility for rare molecular subgroups.
- Strong alignment with precision oncology principles.
- Accelerated learning across multiple disease settings.
From a scientific perspective, basket trials enable researchers to explore whether tumour biology may be more predictive of response than tumour location.
For patients, especially those with rare genomic alterations, these designs can increase access to investigational therapies that might otherwise never be evaluated within their specific cancer type.
Remaining challenges
Despite their advantages, basket trials also present important limitations.
Sample sizes within each basket are often relatively small. While appropriate for signal detection, these cohorts may limit statistical precision.
Biological heterogeneity remains another challenge. Two tumours may share the same mutation yet respond differently because of variations in tumour microenvironment, co-mutations or disease biology.
Interpretation of results can therefore be complex. Positive findings in one basket should not automatically be extrapolated to another.
Regulatory expectations also continue to evolve. Authorities increasingly recognise the value of innovative trial designs, but robust evidence remains essential to support registration decisions. Sponsors must carefully justify analytical strategies, cohort sizes and biomarker selection criteria.
Finally, operational complexity increases alongside the number of participating tumour types, laboratories, vendors and sites.
As basket trials become more sophisticated, collaboration between clinical development, biostatistics and regulatory experts will remain critical to maximise their scientific value.
Basket trial design has become an important component of modern oncology clinical development. By focusing on shared molecular vulnerabilities rather than tumour location alone, these studies support a more efficient and biologically informed approach to therapeutic evaluation.
The need for innovation is particularly urgent in pancreatic cancer, where survival outcomes remain poor and effective treatment options remain limited. Precision oncology offers an opportunity to identify actionable patient subgroups and accelerate the development of targeted therapies that may otherwise be difficult to study using conventional trial models.
The gastrointestinal basket trial discussed in this article demonstrates how biomarker-driven development, MAPK pathway targeting and Simon two-stage methodology can be combined within a practical clinical development strategy. It also highlights the operational expertise required to successfully deliver complex multi-cohort programmes.
Looking ahead, advances in genomic profiling, molecular diagnostics and adaptive trial methodologies are likely to further expand the role of basket trials. As precision oncology continues to evolve, these innovative designs will play an increasingly important role in transforming scientific discoveries into meaningful therapeutic opportunities for patients with pancreatic and gastrointestinal cancers.
Q&A
What is a basket trial in oncology?
A basket trial evaluates a therapy across multiple cancer types that share a common biomarker or molecular alteration.
Why are basket trials important for precision oncology?
They allow researchers to study targeted therapies based on tumour biology rather than tumour location, supporting more personalised treatment approaches.
What are MAPK pathway mutations?
MAPK pathway mutations affect signalling pathways involved in cell growth and survival. Common alterations include KRAS, NRAS, BRAF, MEK and ERK mutations.
What is a Simon two-stage design?
It is a phase II clinical trial design that uses an interim analysis to determine whether a study should stop early for futility or continue enrolling patients.
Why are basket trials relevant in pancreatic cancer research?
Pancreatic cancer has a poor prognosis and relatively few effective treatment options. Basket trials help evaluate targeted therapies in molecularly defined patient populations more efficiently.
TO GO FURTHER

How can we help you with your next project?
Whether you’re looking for a protocol review or a collaboration proposal
Our team is available to discuss your needs with you.
